First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
Background Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified Vaccinia Virus Ankara (MVA) vectored vaccines is a strategy previously shown to provide substantial protective efficacy against P. falciparum infection in United Kingdom adult Phase IIa sporozoite challenge studies (approximately 20–25% sterile protection with similar numbers showing clear delay in time to patency), and greater point efficacy in a trial in Kenyan adults.
... Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's Version
European and Developing Countries Clinical Trials Partnership More from this funder
Swedish International Development Cooperation Agency More from this funder
Austrian Federal Ministry of Science and Research More from this funder
Irish Aid More from this funderExpand funders...
- Public Library of Science Publisher's website
- PLoS ONE Journal website
- Article: e0208328
- Publication date:
- Acceptance date:
- Pubs id:
- Local pid:
- Copyright holder:
- Tiono et al.
- Copyright date:
- © 2018 Tiono et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record